Cardiovascular effects of systemic cancer treatment

Cancer Treatment Reviews

Volumn 37, Issue 4, 2011, Pages 300-311

  Senkus, Elzbieta ^a   Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cancer; Cardiovascular complications; Chemotherapy; Hormonal therapy; Systemic therapy; Targeted therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; ALPHA INTERFERON; ARSENIC TRIOXIDE; BEVACIZUMAB; BLEOMYCIN; BUSULFAN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IMATINIB; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; RETINOIC ACID; RITUXIMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VINCA ALKALOID;

ALLERGIC REACTION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRAIN DISEASE; BRAIN ISCHEMIA; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIOTOXICITY; COMPLETE HEART BLOCK; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TARGETING; EARLY MENOPAUSE; ECG ABNORMALITY; EDEMA; FLU LIKE SYNDROME; FLUID RETENTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BUNDLE BRANCH BLOCK; HEART DEATH; HEART FAILURE; HEART FIBRILLATION; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC MYOPERICARDITIS; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; HYPOTHYROIDISM; KIDNEY INJURY; LUNG EDEMA; LUNG EMBOLISM; MYOCARDITIS; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDITIS; PERICARDIUM FIBROSIS; PERIPHERAL EDEMA; PLEURA EFFUSION; QT PROLONGATION; RAYNAUD PHENOMENON; RETINOIC ACID SYNDROME; REVIEW; RISK FACTOR; SIDE EFFECT; SINUS BRADYCARDIA; ST SEGMENT; ST T SEGMENT CHANGE; STROKE; SUBARACHNOID HEMORRHAGE; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC DYSFUNCTION; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; TORSADE DES POINTES;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INCIDENCE; NEOPLASMS; RISK FACTORS; WORLD HEALTH;

EID: 79953125716     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.11.001     Document Type: Review

References (104)

1. Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004, 109:3122-3131.
2. Bonow R.O., Bennett S., Casey D.E., et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation 2005, 112:1853-1887.
3. Yeh E.T. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006, 57:485-498.
4. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H., et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007, 25:4952-4960.
5. Mertens A.C., Yasui Y., Neglia J.P., et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001, 19:3163-3172.
6. Hooning M.J., Aleman B.M., van Rosmalen A.J., Kuenen M.A., Klijn J.G., van Leeuwen F.E. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006, 64:1081-1091.
7. Jurcut R., Wildiers H., Ganame J., D'hooge J., Paridaens R., Voigt J.U. Detection and monitoring of cardiotoxicity-what does modern cardiology offer?. Support Care Cancer 2008, 16:437-445.
8. Khakoo A.Y., Yeh E.T. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008, 5:655-667.
9. Slordal L., Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf 2006, 29:567-586.
10. Schimmel K.J., Richel D.J., Van den Brink R.B., Guchelaar H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004, 30:181-191.
11. Outomuro D., Grana D.R., Azzato F., Milei J. Adriamycin-induced myocardial toxicity: new solutions for an old problem?. Int J Cardiol 2007, 117:6-15.
12. Floyd J.D., Nguyen D.T., Lobins R.L., Bashir Q., Doll D.C., Perry M.C. Cardiotoxicity of cancer therapy. J Clin Oncol 2005, 23:7685-7696.
13. Youssef G., Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005, 5:233-243.
14. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 2002, 95:1592-1600.
15. Barrett-Lee P.J., Dixon J.M., Farrell C., et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009, 20:816-827.
16. Chen B., Peng X., Pentassuglia L., Lim C.C., Sawyer D.B. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7:114-121.
17. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
18. Perez E.A., Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004, 22:322-329.
19. Bonneterre J., Roche H., Kerbrat P., et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004, 22:3070-3079.
20. Ganz P.A., Hussey M.A., Moinpour C.M., et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol 2008, 26:1223-1230.
21. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001, 19:37-43.
22. Jensen B.V., Skovsgaard T., Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13:699-709.
23. Carver J.R., Shapiro C.L., Ng A., et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007, 25:3991-4008.
24. Tjeerdsma G., Meinardi M.T., van der Graaf W.T., et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999, 81:419-423.
25. Deng S., Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007, 7:129-134.
26. Scully R.E., Lipshultz S.E. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 2007, 7:122-128.
27. Swain S.M., Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004, 130:1-7.
28. Lipshultz S.E., Giantris A.L., Lipsitz S.R., et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002, 20:1677-1682.
29. Ryberg M., Nielsen D., Cortese G., Nielsen G., Skovsgaard T., Andersen P.K. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008, 100:1058-1067.
30. Myers C.E., McGuire W.P., Liss R.H., Ifrim I., Grotzinger K., Young R.C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977, 197:165-167.
31. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23:2900-2902.
32. Milei J., Boveris A., Llesuy S., et al. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am Heart J 1986, 111:95-102.
33. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 26:3777-3784.
34. Sparano J.A., Brown D.L., Wolff A.C. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002, 25:301-311.
35. Mordente A., Meucci E., Martorana G.E., Giardina B., Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001, 52:83-88.
36. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997, 36:11293-11297.
37. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978, 62:865-872.
38. Mackay B., Ewer M.S., Carrasco C.H., Benjamin R.S. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 1994, 18:203-211.
39. Batist G., Ramakrishnan G., Rao C.S., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19:1444-1454.
40. Harris L., Batist G., Belt R., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36.
41. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008; ncbi-n:CD003917.
42. Seymour L., Bramwell V., Moran L.A. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999, 3:145-159.
43. Bates M., Lieu D., Zagari M., Spiers A., Williamson T. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clin Ther 1997, 19:167-184.
44. Hensley M.L., Hagerty K.L., Kewalramani T., et al. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy, Radiation Therapy Protectants. J Clin Oncol 2008, 2:2.
45. Legha S.S., Wang Y.M., Mackay B., et al. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann NY Acad Sci 1982, 393:411-418.
46. Myers C., Bonow R., Palmeri S., et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983, 10:53-55.
47. Jones S., Holmes F.A., O'Shaughnessy J., et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009, 27:1177-1183.
48. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009, 53:2231-2247.
49. Saif M.W., Shah M.M., Shah A.R. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009, 8:191-202.
50. Albini A., Pennesi G., Donatelli F., Cammarota R., De F.S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.
51. Manojlovic N., Babic D., Stojanovic S., Filipovic I., Radoje D. Capecitabine cardiotoxicity - case reports and literature review. Hepatogastroenterology 2008, 55:1249-1256.
52. Dasanu C.A. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008, 7:703-716.
53. Gianni L., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007, 7:67-71.
54. Vallis K.A., Pintilie M., Chong N., et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 2002, 20:1036-1042.
55. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001, 344:783-792.
56. Hayes D.F., Picard M.H. Heart of darkness: the downside of trastuzumab. J Clin Oncol 2006, 24:4056-4058.
57. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
58. de A.E., Bedard P.L., Suter T., Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?. Target Oncol 2009, 4:77-88.
59. Yavas O., Yazici M., Eren O., Oyan B. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly 2007, 137:556-558.
60. Telli M.L., Hunt S.A., Carlson R.W., Guardino A.E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007, 25:3525-3533.
61. Suter T.M., Cook-Bruns N., Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004, 13:173-183.
62. Slamon D, Eiermann W, Robert N, et al. Phase III Trial Comparing AC-T with AC-TH and with TCH in the Adjuvant Treatment of HER2 positive Early Breast Cancer Patients: Second Interim Efficacy Analysis. Abstr.29th Annual San Antonio Breast Cancer Symposium 2006.
63. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
64. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
65. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
66. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
67. Speyer J. Cardiac dysfunction in the trastuzumab clinical experience. J Clin Oncol 2002, 20:1156-1157.
68. Grazette L.P., Boecker W., Matsui T., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004, 44:2231-2238.
69. Perez E.A., Koehler M., Byrne J., Preston A.J., Rappold E., Ewer M.S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008, 83:679-686.
70. Spector N.L., Yarden Y., Smith B., et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA 2007, 104:10607-10612.
71. Azim H., Azim H.A., Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 2009, 35:633-638.
72. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006, 24:1363-1369.
73. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186-193.
74. Shih T., Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006, 28:1779-1802.
75. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
76. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
77. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
78. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
79. Pouessel D., Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008, 53:376-381.
80. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
81. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
82. Joensuu H. Cardiac toxicity of sunitinib. Lancet 2007, 370:1978-1980.
83. Strevel E.L., Ing D.J., Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007, 25:3362-3371.
84. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
85. Atallah E., Durand J.B., Kantarjian H., Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007, 110:1233-1237.
86. Vogelvang T.E., van der Mooren M.J., Mijatovic V., Kenemans P. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. Drugs 2006, 66:191-221.
87. Nandur R., Kumar K., Villablanca A.C. Cardiovascular actions of selective estrogen receptor modulators and phytoestrogens. Prev Cardiol 2004, 7:73-79.
88. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003, 18:937-947.
89. Meier C.R., Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998, 45:608-612.
90. Bushnell C.D., Goldstein L.B. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 2004, 63:1230-1233.
91. Cushman M., Costantino J.P., Bovill E.G., et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol 2003, 120:109-116.
92. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
93. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420-2425.
94. Nabholtz J.M., Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf 2006, 29:785-801.
95. Lenihan D.J., Esteva F.J. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 2008, 13:1224-1234.
96. Altena R., Perik P.J., van Veldhuisen D.J., de Vries E.G., Gietema J.A. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009, 10:391-399.
97. Galderisi M., Marra F., Esposito R., Lomoriello V.S., Pardo M., de Divitiis O. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007, 5:4.
98. Karakurt C., Kocak G., Ozgen U. Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 2008, 25:880-887.
99. Mavinkurve-Groothuis A.M., Groot-Loonen J., Bellersen L., et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer 2009, 52:631-636.
100. Jones A.L., Barlow M., Barrett-Lee P.J., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009, 100:684-692.
101. Blaes A.H., Gaillard P., Peterson B.A., Yee D., Virnig B. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat 2010.
102. van Heeckeren W.J., Ortiz J., Cooney M.M., Remick S.C. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?. J Clin Oncol 2007, 25:2993-2995.
103. Wadhwa D., Fallah-Rad N., Grenier D., et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009, 117:357-364.
104. Hershman D.L., Neugut A.I. Anthracycline cardiotoxicity: one size does not fit all!. J Natl Cancer Inst 2008, 100:1046-1047.